Summary
Boston Scientific Corporation (BSX) announced on June 24, 2021, that it has exercised an option to acquire the remaining shares of Farapulse, Inc., a company specializing in pulsed field ablation systems for atrial fibrillation treatment. This strategic acquisition aims to enhance BSX's offerings in the cardiac rhythm management and electrophysiology markets. The transaction involves an upfront payment of $450 million, adjusted to approximately $295 million after accounting for BSX's existing stake, debt, and other closing adjustments. Additional payments, including up to $125 million tied to clinical and regulatory milestones and future revenue-based considerations, are also part of the deal. The acquisition is expected to close in the third quarter of 2021, subject to standard closing conditions. This move signifies BSX's commitment to expanding its presence in innovative therapeutic technologies.
Key Highlights
- 1Boston Scientific (BSX) is acquiring the remaining shares of Farapulse, Inc., a developer of pulsed field ablation systems.
- 2The acquisition aims to strengthen BSX's position in the treatment of atrial fibrillation.
- 3The total transaction value includes an upfront payment of approximately $295 million (after adjustments) and potential milestone and revenue-based payments.
- 4The deal is expected to close in the third quarter of 2021.
- 5Farapulse's technology offers a non-thermal ablation treatment for atrial fibrillation.
- 6The announcement was made via a press release filed as an exhibit to the 8-K.